Sixth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification
Full-year 2015 financial results : Creating the platform for growth
Start of Phase I clinical trial of monalizumab in combination with durvalumab
Number of shares and voting rights of Innate Pharma as at February 3, 2016
Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology
Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program
Number of shares and voting rights of Innate Pharma as at January 6, 2016
Innate Pharma announces its financial calendar for 2016
Full-year report on Innate Pharma's liquidity contract with Gilbert Dupont
Upcoming investor conferences
